{"id":40373,"date":"2020-11-21T11:06:47","date_gmt":"2020-11-21T16:06:47","guid":{"rendered":"https:\/\/sciencebusiness.technewslit.com\/?p=40373"},"modified":"2020-11-23T11:44:25","modified_gmt":"2020-11-23T16:44:25","slug":"infographic-vaccines-boost-biotech-shares","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=40373","title":{"rendered":"Infographic – Vaccines Boost Biotech Shares"},"content":{"rendered":"
\"Biotech<\/a>
Click on image for full-size view (Statista)<\/figcaption><\/figure>\n

21 Nov. 2020. The clinical trial successes so far of vaccines to protect against Covid-19 infections is providing much-needed hope for an end to the pandemic. News of those trials fueled healthy share price rises for the biotechnology companies developing the vaccines, documented this week by business research company Statista<\/a>, and shown in this weekend’s infographic.<\/p>\n

As reported by Science & Enterprise<\/a> and throughout the news media this week, Covid-19 vaccines developed by Moderna and BioNTech, based on messenger RNA, reported efficacy rates exceeding 90 percent in late-stage trials. And the vaccine developed by University of Oxford, derived from an adenovirus in chimpanzees then genetically engineered to resemble SARS-CoV-2 spike proteins, scored particularly well with older trial participants<\/a> in a mid-stage trial.<\/p>\n

Those successes powered share prices for Moderna, up 354 percent, and BioNT gainech, up 167 percent since the start of 2020. Those share price gains, however, have not rubbed off on the biotech companies’ drug-maker collaborators, also sponsors of the late-stage trials. The share price for AstraZeneca, partnering with Oxford, rose only 8 percent, while BioNTech’s partner Pfizer has seen its share price drop by 2 percent since January. The two pharmaceutical companies make a broad range of products beyond Covid-19 vaccines that affect their share prices.<\/p>\n

More from Science & Enterprise:<\/p>\n